Mary Wilson
Well-known member
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal.
Posted Date: March 25th, 2022
DOI: https://doi.org/10.21203/rs.3.rs-1479515/v1
Lize Cuypers, Els Keyaerts, Samuel Hong, Sarah Gorissen, Soraya Maria Menezes, Marick Starick, Jan Van Elslande, Matthias Weemaes, Tony Wawina-Bokalanga, Bert Vanmechelen, Bram Van Holm, Mandy Bloemen, Jean-Michel Dogne, François Dufrasne, Keith Durkin, Jean Ruelle, Ricardo De Mendonca, COVID-19 Genomics Belgium Consortium, Elke Wollants, Pieter Vermeersch, Caroline Bouloffe, Achille Djiena, Caroline Broucke, Boudewijn Catry, Katrien Lagrou, Marc Van Ranst, Johan Neyts, Guy Baele, Piet Maes, Emmanuel André, Simon Dellicour, Johan Van Weyenbergh
Abstract
COVID-19 vaccination has resulted in excellent protection against fatal disease, including in the elderly. However, risk factors for post-vaccination fatal COVID-19 are largely unknown. We comprehensively studied three large nursing home outbreaks (20-35% fatal cases) by combining SARS-CoV-2 aerosol monitoring, whole-genome phylogenetic analysis, and immunovirological pro ling by digital nCounter transcriptomics. Phylogenetic investigations indicated each outbreak stemmed from a single introduction event, though with different variants (Delta, Gamma, and Mu). SARS-CoV-2 was detected in aerosol samples up to 52 days after the initial infection. Combining demographic, immune and viral parameters, the best predictive models for mortality comprised IFNB1 or age, viral ORF7a and ACE2 receptor transcripts. Comparison with published pre-vaccine fatal COVID-19 signatures and reanalysis of single- cell RNAseq data highlights the unique immune signature in post-vaccine fatal COVID-19 outbreaks. A multi-layered strategy including environmental sampling, immunomonitoring, and early antiviral therapy should be considered to prevent post-vaccination COVID-19 mortality in nursing homes.
https://assets.researchsquare.com/f...-7386-42ce-a273-dbbb3f1afb63.pdf?c=1648247801
Posted Date: March 25th, 2022
DOI: https://doi.org/10.21203/rs.3.rs-1479515/v1
Lize Cuypers, Els Keyaerts, Samuel Hong, Sarah Gorissen, Soraya Maria Menezes, Marick Starick, Jan Van Elslande, Matthias Weemaes, Tony Wawina-Bokalanga, Bert Vanmechelen, Bram Van Holm, Mandy Bloemen, Jean-Michel Dogne, François Dufrasne, Keith Durkin, Jean Ruelle, Ricardo De Mendonca, COVID-19 Genomics Belgium Consortium, Elke Wollants, Pieter Vermeersch, Caroline Bouloffe, Achille Djiena, Caroline Broucke, Boudewijn Catry, Katrien Lagrou, Marc Van Ranst, Johan Neyts, Guy Baele, Piet Maes, Emmanuel André, Simon Dellicour, Johan Van Weyenbergh
Abstract
COVID-19 vaccination has resulted in excellent protection against fatal disease, including in the elderly. However, risk factors for post-vaccination fatal COVID-19 are largely unknown. We comprehensively studied three large nursing home outbreaks (20-35% fatal cases) by combining SARS-CoV-2 aerosol monitoring, whole-genome phylogenetic analysis, and immunovirological pro ling by digital nCounter transcriptomics. Phylogenetic investigations indicated each outbreak stemmed from a single introduction event, though with different variants (Delta, Gamma, and Mu). SARS-CoV-2 was detected in aerosol samples up to 52 days after the initial infection. Combining demographic, immune and viral parameters, the best predictive models for mortality comprised IFNB1 or age, viral ORF7a and ACE2 receptor transcripts. Comparison with published pre-vaccine fatal COVID-19 signatures and reanalysis of single- cell RNAseq data highlights the unique immune signature in post-vaccine fatal COVID-19 outbreaks. A multi-layered strategy including environmental sampling, immunomonitoring, and early antiviral therapy should be considered to prevent post-vaccination COVID-19 mortality in nursing homes.
https://assets.researchsquare.com/f...-7386-42ce-a273-dbbb3f1afb63.pdf?c=1648247801